[go: up one dir, main page]

HK1207006A1 - Daptomycin formulations and uses thereof - Google Patents

Daptomycin formulations and uses thereof Download PDF

Info

Publication number
HK1207006A1
HK1207006A1 HK15107795.5A HK15107795A HK1207006A1 HK 1207006 A1 HK1207006 A1 HK 1207006A1 HK 15107795 A HK15107795 A HK 15107795A HK 1207006 A1 HK1207006 A1 HK 1207006A1
Authority
HK
Hong Kong
Prior art keywords
daptomycin formulations
lyophilised
daptomycin
formulations
useful
Prior art date
Application number
HK15107795.5A
Other languages
English (en)
Chinese (zh)
Inventor
Jim Alexiou
Noel Norris
Andrew Knill
Darryl Whittaker
Original Assignee
Hospira Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1207006(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Australia Pty Ltd filed Critical Hospira Australia Pty Ltd
Publication of HK1207006A1 publication Critical patent/HK1207006A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15107795.5A 2012-09-11 2013-09-11 Daptomycin formulations and uses thereof HK1207006A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261699570P 2012-09-11 2012-09-11
US201261699570P 2012-09-11
US201361839699P 2013-06-26 2013-06-26
US201361839699P 2013-06-26
PCT/IB2013/002191 WO2014041425A1 (fr) 2012-09-11 2013-09-11 Formulations de daptomycine et leurs utilisations

Publications (1)

Publication Number Publication Date
HK1207006A1 true HK1207006A1 (en) 2016-01-22

Family

ID=50277707

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107795.5A HK1207006A1 (en) 2012-09-11 2013-09-11 Daptomycin formulations and uses thereof

Country Status (21)

Country Link
US (4) US9655946B2 (fr)
EP (2) EP4066849B1 (fr)
AU (2) AU2013316779A1 (fr)
BR (1) BR112015005400B1 (fr)
CA (1) CA2884484C (fr)
CL (1) CL2015000608A1 (fr)
CY (1) CY2200004T2 (fr)
DE (1) DE13837694T1 (fr)
DK (1) DK2895187T1 (fr)
ES (2) ES3018415T3 (fr)
HK (1) HK1207006A1 (fr)
HU (2) HUE071031T2 (fr)
IL (1) IL237652B (fr)
MX (1) MX366122B (fr)
NZ (3) NZ742241A (fr)
PL (1) PL4066849T3 (fr)
SA (1) SA515360129B1 (fr)
SG (1) SG11201506113WA (fr)
TN (1) TN2015000090A1 (fr)
WO (1) WO2014041425A1 (fr)
ZA (1) ZA201502310B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013316779A1 (en) * 2012-09-11 2015-04-02 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
US10933019B2 (en) 2016-10-21 2021-03-02 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
CA3070660A1 (fr) 2017-08-31 2019-03-07 Xellia Pharmaceuticals Aps Formulations de daptomycine
CN110339342A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素的盐或含盐的组合物及其制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
WO2021131314A1 (fr) * 2019-12-26 2021-07-01 ニプロ株式会社 Formulation lyophilisée stable contenant de la daptomycine
CN115427038A (zh) 2020-02-03 2022-12-02 建新公司 治疗与溶酶体贮积病相关的神经系统症状的方法
WO2021183752A1 (fr) 2020-03-12 2021-09-16 Baxter International Inc. Formulations de daptomycine contenant une association de sorbitol et de mannitol
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat
CN115590825B (zh) * 2022-10-20 2024-02-02 安士制药(中山)有限公司 一种注射用达托霉素及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560906A (en) * 1995-03-27 1996-10-01 Oral Technology Laboratories, Inc. Non-alcoholic antimicrobial mouthwash for removal of dental plaque
PL203689B1 (pl) * 1998-09-25 2009-11-30 Cubist Pharmaceuticals Zastosowanie daptomycyny
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (fr) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Procedes de preparation de lipopeptides purifies
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
US8003673B2 (en) * 2005-05-31 2011-08-23 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
TWI548414B (zh) * 2009-11-23 2016-09-11 庫比斯特製藥有限責任公司 達托黴素(daptomycin)組合物及相關方法
EP2504020A4 (fr) * 2009-11-23 2013-05-29 Eagle Pharmaceuticals Inc Formulations de daptomycine
SI2887953T1 (en) 2012-08-23 2018-02-28 Mylan Laboratories Limited IMPROVED DAPTOMICINE FORMATION FORMULATION
AU2013316779A1 (en) * 2012-09-11 2015-04-02 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof

Also Published As

Publication number Publication date
US9655946B2 (en) 2017-05-23
HUE071031T2 (hu) 2025-07-28
CA2884484C (fr) 2021-01-19
ES2552754T1 (es) 2015-12-02
CA2884484A1 (fr) 2014-03-20
MX366122B (es) 2019-06-27
US20170216396A1 (en) 2017-08-03
CY2200004T2 (el) 2016-02-10
EP4066849C0 (fr) 2025-03-05
TN2015000090A1 (en) 2016-06-29
AU2013316779A1 (en) 2015-04-02
US20150313958A1 (en) 2015-11-05
IL237652B (en) 2020-06-30
EP2895187A1 (fr) 2015-07-22
BR112015005400B1 (pt) 2022-03-08
HUE13837694T1 (hu) 2016-04-28
IL237652A0 (en) 2015-04-30
MX2015003164A (es) 2015-12-16
DK2895187T1 (da) 2015-11-16
DE13837694T1 (de) 2015-12-31
CL2015000608A1 (es) 2015-11-06
NZ741342A (en) 2019-10-25
NZ706286A (en) 2018-05-25
EP2895187A4 (fr) 2015-12-02
ZA201502310B (en) 2019-09-25
NZ742241A (en) 2019-08-30
EP4066849A1 (fr) 2022-10-05
PL4066849T3 (pl) 2025-06-16
BR112015005400A2 (pt) 2017-07-04
US20180177843A1 (en) 2018-06-28
AU2018217322A1 (en) 2018-09-06
EP4066849B1 (fr) 2025-03-05
WO2014041425A1 (fr) 2014-03-20
ES3018415T3 (es) 2025-05-16
SA515360129B1 (ar) 2016-08-15
US10357535B2 (en) 2019-07-23
US20200237858A1 (en) 2020-07-30
SG11201506113WA (en) 2015-09-29
AU2018217322B2 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
HK1207006A1 (en) Daptomycin formulations and uses thereof
CA2883095C (fr) Anticorps et formulations proteiques
WO2014052836A3 (fr) Procédés et compositions de traitement d'une infection
WO2013184755A3 (fr) Inhibiteurs de seca et leurs procédés de fabrication et d'utilisation
ZA201500970B (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
PT2748165T (pt) Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas
ZA201307963B (en) 1,6- diazabicyclo [3,2,1] octan-7 one derivatives and their use in the treatment of bacterial infections
ZA201508529B (en) Bacterial fermentation methods and compositions
EP3033351A4 (fr) Méthodes et compositions antivirales comprenant des molécules bactériennes probiotiques
EP2971030B8 (fr) Compositions d'oligosaccharide, glycoprotéines et procédés pour produire celles-ci dans des procaryotes
WO2015058132A3 (fr) Anticorps anti-rspo et leurs méthodes d'utilisation
EP3047006A4 (fr) Compositions assouplissantes comprenant des solutions de fruit fermentées et leurs procédés de fabrication et d'utilisation
PH12014501369A1 (en) Oral care compositions
SI2575971T1 (sl) Kombinirani rastlinski izvlečki za uporabo pri zdravljenju okužb z mikrobi
EP3135755A4 (fr) Souche de bifidobacterium breve cbt br3 pour favoriser la croissance et composition alimentaire fonctionnelle la contenant pour favoriser la croissance
WO2014093999A3 (fr) Boisson alcaline
EP3165599A4 (fr) Nouvelle bactérie d'acide lactique et composition comprenant cette bactérie d'acide lactique
ZA201402452B (en) Novel pyrimethanil formulations and uses thereof in the treatment of crops
MX363631B (es) Composiciones y metodos para tratar infecciones bacterianas.
PL2753182T3 (pl) Środki czynne przeciw szczepom Pseudomonas powodującym choroby gnilne w uprawach grzybów, ich zastosowanie i zawierające je kompozycje
ZA201404826B (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2015073788A3 (fr) Méthodes et compositions pour le traitement du cytomégalovirus humain
SI2683418T1 (sl) Produkti za vezavo bakterijskih toksinov in njihovo odstranjevanje pri zdravljenju lokalnih okužb in izdelava le-teh
WO2015108605A3 (fr) Production microbienne d'alcools à chaîne moyenne ramifiée, tels que le 4-méthylpentanol
ZA201308256B (en) Uses, methods and biological compositions of the genus paecilomyces for the control, prevention and eradication of phytoparasites in solanaceae cultures